Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2026

Joint Venture Deals in Pharmaceuticals and Biotechnology

Understand how pharmaceutical and biotechnology companies use joint ventures to combine capabilities, share investment and pursue new development and commercial opportunities.

Joint Venture Deals in Pharmaceuticals and Biotechnology provides comprehensive intelligence on 458 joint venture deals announced across the pharmaceutical and biotechnology sectors.

The report examines how companies are using joint ventures to bring together complementary assets, technologies, expertise, funding and commercial capabilities while sharing the risks and responsibilities associated with developing new opportunities.

Rather than simply identifying transactions, the report enables users to understand who is forming joint ventures, where activity is taking place, how joint ventures are structured, and what can be learned from leading transactions and publicly available contract documents.

It provides a practical intelligence and benchmarking resource for business development, corporate strategy, licensing, legal and senior management teams evaluating joint venture opportunities or considering alternative partnering structures.

Understand the joint venture deal landscape

The report provides detailed analysis of joint venture activity from 2016 to 2026, including:

• Joint venture dealmaking trends by year
• Stage of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active joint venture dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering joint ventures
• The evolving role of joint ventures within life sciences partnering
• This enables users to identify areas of concentrated activity, understand how joint ventures are being applied across the industry and assess the companies most actively using this form of partnership.
• Examine how joint ventures are structured
• Joint ventures differ fundamentally from conventional licensing and collaboration agreements because the partners establish a shared business or operating structure around a defined opportunity.

The report examines the structure of joint venture agreements and provides real-world examples that can help users consider areas including:

• Ownership and equity participation
• Partner contributions
• Funding and investment commitments
• Governance and decision-making
• Management responsibilities
• Intellectual property rights
• Development and commercialization responsibilities
• Geographic and market rights
• Term and termination provisions
• Financial arrangements where disclosed
• This provides useful reference points for companies assessing whether a joint venture is an appropriate partnering model and preparing for discussions with prospective partners.
• Benchmark leading transactions and dealmakers
• The report identifies leading joint venture transactions by disclosed deal value and profiles the Top 25 most active joint venture dealmakers.
• Users can examine which companies are repeatedly using joint ventures, the types of opportunities attracting these partnerships and how individual companies are applying the model within their wider partnering strategies.
• This can support competitor analysis, partner identification and the assessment of precedent transactions.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying joint venture contract documents.
• These agreements can reveal significantly more detail than company announcements alone, enabling users to examine how selected joint ventures address ownership, governance, funding, intellectual property, responsibilities, termination and other negotiated provisions.
• For teams considering or negotiating a joint venture, these real-world agreements provide valuable insight into how comparable transactions have been documented in practice.
• Comprehensive joint venture deal directory
• The report includes a comprehensive directory of 458 joint venture deals, allowing users to identify and investigate transactions relevant to their own requirements.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Evaluate joint venture opportunities, identify active participants and examine comparable transactions.
• Corporate Strategy teams
• Understand how joint ventures are being used to combine capabilities, enter new markets, share investment and pursue strategic opportunities.
• Legal and Transaction teams
• Review agreement structures, governance arrangements and real contract language from relevant transactions.
• Competitive and Market Intelligence teams
• Track joint venture activity by company, therapy area, technology and industry sector.
• Senior Management and Investors
• Assess the strategic rationale, structure and participants behind significant joint venture activity.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying deal intelligence to the customer's own business, technologies, assets or strategic objectives.
• Depending on requirements, this can include relevant comparable transactions, potential partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's partnering situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.